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Abstract - Clostridium difficile-associated diarrhea (CDAD) has been recognized as the leading cause of diarrhea world-
wide. In the last five years, it has become the leading cause of diarrhea in the Clinical Center of Vojvodina (CCV) as well. 
The aim of this study was to determine the epidemiology and total cost of treatment for all patients with Clostridium 
difficile-associated diarrhea hospitalized at the Infectious Disease Clinic of the CCV; to analyze the costs of treatment with 
regard to therapeutic approach; to compare the costs of treatment in each year of the investigated period related to the 
number of patients, and to analyze the outcome of treatment. The study was retrospective, and the data were collected 
from the medical records of 472 patients with Clostridium difficile diarrhea treated from 2008 to 2012 and analyzed. Of 
the total 472 patients with CDAD, 54.23% were female and the average age was 65.84. A statistically significant major-
ity of them had been previously treated in other hospitals and a minority in ambulatory settings (395 inpatients vs. 77 
outpatients, p=0.000, p<0.05). Of the 395 previously hospitalized patients, most were from the Clinic of Urology of the 
CCV (58, 14.68%). When comparing therapeutic options, oral vancomycin was significantly more frequently used than 
other protocols. The average mortality rate during the study period was 6.51%. In this period, total hospital costs related 
to Clostridium difficile diarrhea in the Infectious Disease Clinic were $636,679.92. Implementation of infection-control 
measures and a restricted use of antibiotics would result in a great reduction in material costs.
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INTRODUCTION
Clostridium difficile-associated diarrhea (CDAD) has 
been recognized as the leading cause of diarrhea in 
healthcare settings worldwide. In the last five years, 
it has become the leading cause of diarrhea in the 
Clinical Center of Vojvodina (CCV) as well. It is also 
rapidly spreading outside hospitals and becoming a 
common cause of diarrhea in the community (Lo 
Vecchio et al., 2012).
Clostridium  difficile  (CD)  is  a  gram-positive, 
anaerobic, spore-forming bacillus. It is responsible 
for different clinical presentations varying from the 
asymptomatic carrier state to fulminant colitis with 
toxic megacolon and perforation (Vaishnavi, 2010).
Clostridium difficile is identified as the cause of 15-
20% of all antibiotic-associated diarrheas. In the last 
decades, the total number of Clostridium difficile in-
fections (CDI) has increased, along with the number 
of cases with severe and fatal complications. Inci-
dence and severity has dramatically increased since 
the appearance of a hypervirulent strain in 2000, es-
pecially in healthcare settings. The emergence of hy-
pervirulent strains, coupled with indiscriminate use 58 SANDRA STEFAN-MIKIĆ ET AL.
of antimicrobials and inadequate infection control 
measures in hospitals are the primary factors con-
tributing to the recent C. difficile outbreaks (Vermaet 
et al., 2011). Infection control in healthcare settings 
includes preventing the spread of infection (proper 
hand hygiene, use of personal protective equipment, 
environmental decontamination, isolation or cohort 
nursing and adequate treatment of CDAD cases.
This virulent strain has been associated with in-
creased production of toxins A+B, fluoroquinolone 
resistance, and the production of binary toxin. The 
role of binary toxin is not clear but it may syner-
gistically increase the virulence of toxins A and B. 
Based on data from the Centers of Disease Control 
and Prevention, the virulent strain NAP1/027 has 
been reported in most states throughout the US and 
in several countries in Europe. In the most recent 
data from European studies, the mean incidence of 
healthcare-associated CDI is 4.1 per 1 000 inpatient 
days (Bauer et al., 2011). In US population studies, 
CDI incidence rates range from 6.9 to 46 per 100 000 
persons/year (Lo Vecchio et al., 2012).
The  high  costs  attributable  to  CDI  produce  a 
substantial burden on healthcare systems worldwide 
(Verma et al., 2011). In US-based studies, estimated 
costs ranged from $2,871 to $4,846 per case for pri-
mary CDI and from $13,655 to $18,067 per case for 
recurrent CDI. US-based studies in special popula-
tions  (subjects  with  irritable  bowel  disease,  surgi-
cal inpatients, and patients treated in the intensive 
care unit) showed that additional costs were need-
ed, ranging from $6,242 to $90,664. Non-US-based 
studies showed an estimated cost of $5,243 to $8,570 
per case for primary CDI and $13,655 per case for re-
current CDI. In both primary and recurrent cases of 
CDI, economic healthcare costs are high. These costs 
related to CDI justify the use of additional resourc-
es for CDI prevention and control (Ghantoji et al., 
2010). Successful prevention of CDAD in healthcare 
settings can be achieved by comprehensive infection 
control measures, including appropriate antimicro-
bial use, enforcement of infection control practices 
and better environmental cleaning (Eckstein et al., 
2007).
Preventing healthcare-associated infections, in-
cluding CDAD, would be beneficial to the whole of 
society. However, preventive measures can be expen-
sive. In order to support these preventive efforts, it is 
important to gain better insights into the outcomes 
of CDAD (Perencevich et al., 2007). 
Our aim was to estimate the total costs of CDI 
treatments for all patients at the Infectious Diseases 
Clinic, Clinical Center of Vojvodina, between 2008-
2012, to present and compare the costs of treatment 
for patients with CDI taking into account the thera-
peutic approach, type of health facility where the pa-
tient had been previously treated or infected by C. 
difficile (comorbidities), and to analyze the costs over 
the years due to the number of patients and outcome 
of treatment.
MATERIALS AND METHODS
The study was a retrospective case study in which 
data collected from the medical records of all patients 
with  CDI  at  the  Infectious  Diseases  Clinic  of  the 
Clinical Center of Vojvodina in Novi Sad from 2008 
to 2012, were analyzed; 472 patients with Clostridium 
difficile infection were investigated. The diagnosis of 
Clostridium  difficile-associated  diarrhea  was  based 
on laboratory identification of toxin A and/or B by 
toxin enzyme immunoassays (ELISA).
The following data were collected for all patients: 
patient demoFig.ics (age, gender), length of stay, pre-
vious hospitalization, therapeutic protocol used for 
treatment of initial episode and recurrence, length 
of hospitalization, total hospital cost and outcome of 
therapy.
All  financial  parameters  are  converted  to  US 
dollars  using  the  official  currency  exchange  rate 
of the National Bank of Serbia (NBS) in 2013 (on 
19.04.2013,  1  $=85.11  RSD):  the  inflation  rate  in 
2013 was also taken into consideration
RESULTS
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male and 54.23% were female (p=0.31; p>0.05). Th   e 
average age was 65.84; the youngest was 2 years old 
and the oldest patient was 92 years old.
A statistically signifi  cant majority of the patients 
had been previously treated in other hospitals and the 
minority in ambulatory settings (395 inpatients vs. 77 
outpatients, p= 0.00, p <0.05). Among the 395 previ-
ously hospitalized patients, 58 (14.68%) were infected 
by C. diffi   cile at the Clinic of Urology, 42 (10.63%) at 
the Clinic of Abdominal and Transplantation Surgery, 
42 (10.63%) at the Institute for Pulmonary Diseases, 
36 (9.11%) patients at the Clinic of Gastroenterology 
and Hepatology, 34 (8.6%) at the Institute of Cardiol-
ogy, 27 (6.83%) at the Clinic of Neurology, 21 (5.31%) 
at the Orthopedic Clinic, Clinic of Endocrinology, 
Clinic of Nephrology and Immunology, 10 (2.53%) 
at the Clinic of Hematology, 8 (2.02%) at the Clinic 
Fig. 1. Clinics where patients with Clostridium diffi   cile-associated diarrhea were previously treated.
Fig. 2. Total hospital costs related to presence of Clostridium diffi   cile infection from 2008 to 2012 at the Infectious Diseases Clinic, Clini-
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for Vascular Surgery, and 6 (1.51%) at the Clinic for 
Medical Rehabilitation and Clinic for Neurosurgery, 
CCV (Fig. 1), while other health facilities were repre-
sented in lower percentages.
Total hospital costs related to presence of CDI 
in the period from 2008 to 2012 at the Infectious 
Diseases Clinic, Clinical Center of Vojvodina, were$ 
636,679.92 (Fig. 2). The total hospital costs of treat-
ment for CDI patients in 2008, 2009, 2010, 2011 and 
2012  were  $132,592.65,  $108,887.78,  $156,232.99, 
$133,445.15 and $105,521.35 respectively. The high-
est  cost  for  the  treatment  of  a  single  patient  was 
$7,534.
Total hospital costs of treatment of initial CDI 
were $496,667.80 (Fig. 3).
Total  hospital  costs  of  treatment  of  recurrent 
CDI were $138,374.99 (Fig. 4). The average cost of 
treatment per case of initial CDI was about $1,149.03 
and $1,081.74 for recurrent CDI (p=0.14, p>0.05). 
The average cost of treatment per day of CDI was 
about $1,131.90. There was no statistically significant 
difference between the average cost of treatment per 
day of initial and recurrent CDI ($97.19 vs. $103.47, 
p=0.67, p> 0.05). In the investigated five-year period, 
the highest total costs for the treatment of CDI pa-
tients were found at the Clinic of Urology, CCV, and 
came to $97,456.42 (15.13%).
Of the 472 cases, for the treatment of the initial 
episode of CDI, in 88 (18.64%) metronidazole in a 
dose 400-500 mg was given orally 3 times daily, 63 
patients (13.34%) were treated with oral vancomy-
Fig. 3. Costs of treatment of initial Clostridium difficile infection.
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cin in a dose of 125 mg 4 times daily, 190 (40.25%) 
were treated with oral vancomycin in a dose of 250 
mg  4  times  daily,  and  131  (27.75%)  were  treated 
with a combination therapy of oral vancomycin and 
parenteral metronidazole. Comparing the therapeu-
tic options, the significantly prevailing therapeutic 
protocol was oral vancomycin in a dose of 250 mg 4 
times daily (p = 0.00, p <0.05) (Fig. 5).
Ten-day costs for initial CDI with oral metroni-
dazole in the CCV were $3.44, which is significantly 
lower than the oral vancomycin therapy option in a 
dose of 125 mg 4 times daily (p<0.000, p<0.05). The 
therapeutic option with oral vancomycin in a dose 
of 250 mg 4 times daily that costs $48.98 is statisti-
cally significantly more expensive compared to the 
treatment option with oral vancomycin in a dose of 
125 mg 4 times daily, which costs $24.49 (p<0.000, 
p<0.05) (Table 1). Recurrent C. difficile infection oc-
curred in 124/472 (26.27%) patients. There was no 
significant difference between mean length of stay in 
the initial episode of CDI compared to recurrent CDI 
(12.13 vs. 12.32, p=0.96, p>0.05). Mortality rates in 
2008, 2009, 2010, 2011 and 2012 were 11 (11.11%), 
8 (10.38%), 4 (3.66%), 4 (3.96%) and 3 (3.48%), re-
spectively. Mortality rates were significantly higher 
in 2008 and 2009 compared to 2010, 2011 and 2012 
(p =0,046, p<0.05). The average mortality rate during 
the study period was 6.51%.
DISCUSSION
Clostridium difficile-associated diarrhea is the most 
common  cause  of  nosocomial  diarrhea.  The  inci-
dence and severity are constantly rising (Ricciardi 
et al., 2007). The epidemiology of CD infection has 
radically changed in the last decade (Deneve et al., 
2009), which could be partly a result of the new and 
virulent strain of CD labeled NAP-01 (North Ameri-
can Pulsed-Field Type 1) ribotype 027 (Vermaet et 
Fig. 5. Therapeutic options for initial Clostridium difficile infection.
Table 1. Costs of ten-day antimicrobial treatment of initial Clostridium difficile infection.
Therapeutic protocols
Cost of ten-day treatment 
(US dollars)
Oral dose of 440 mg metronidazole 3 times daily 3.44
Oral dose of 125 mg vancomycin 4 times daily 24.49
Oral dose of 250 mg vancomycin 4 times daily 48.98
Combined therapy with oral dose of 500 mg vancomycin daily and 500 mg parenteral 
metronidazole 3 times daily
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al., 2011), but the changes in the epidemiology of 
CDI also occurred in countries where the incidence 
of this strain was relatively low (Kovačević, 2012). 
There are neither data on presence of this C. difficile 
strain in our country, nor official epidemiological re-
ports about the rate of incidence.
Our investigation included 472 patients hospital-
ized from 2008-2012 at the Clinic of Infectious Dis-
eases with confirmed diagnosis of diarrhea caused 
by Clostridium difficile. A total of 99 patients were 
hospitalized in 2008, 77 patients were hospitalized in 
2009, 109 in 2010, 101 in 2011 and 86 in 2012. We 
detected a statistically significant increase in number 
of hospitalized patients in 2010 compared to 2009 
(p = 0.01). Despite the fact that the majority of the 
patients treated at the Clinic for Infectious Diseases 
suffered from CDI, only a few cases (i.e. 7 patients) 
were registered at the Clinic during the five-year pe-
riod of monitoring. 
Until five years ago, hospitalized patients with a 
diagnosis of diarrhea caused by CD in the Clinical 
Center of Vojvodina were sporadic, but from 2008-
2012 the rising number of cases became a major con-
cern, which corresponds to the recent epidemiologi-
cal data in the world literature. With the appearance 
of the new strain, the incidence in Europe started 
rising, first in England, then in Ireland, Netherlands, 
Belgium,  Luxembourg  and  France  (Stevens  et  al., 
2011).
Our demographics data showed that the aver-
age age of the patients was 65.84 and that 54.23% 
of  patients  were  female.  This  corresponds  to  the 
data from literature that the frequency and sever-
ity of the disease increases in the population over 
65 years. This population is at high risk because of 
recurrent hospitalizations and comorbidities. Stud-
ies have also confirmed the prevalence of females 
with CDI (King et al., 2011, Cohen et al., 2010. The 
factors that significantly increase the risk of CDI in-
clude the use of antibiotics, length of hospital stay, 
previous hospitalizations, surgical procedures, co-
morbidities and treatment with antacids (Hensgens 
et al., 2012).
Statistically significantly more patients were pre-
viously treated in a hospital, compared to outpatients 
(395 vs. 77, p= 0.000, p <0.05). Among 395 patients 
previously treated at another healthcare facility where 
they acquired Clostridium difficile, the majority came 
from the Clinic of Urology – 58 patients (14.68%), 
42 (10.63%) at the Clinic of Abdominal and Trans-
plantation Surgery, 42 (10.63%) at the Institute for 
Pulmonary Diseases, and 36 (9.11%) at the Clinic of 
Gastroenterology and Hepatology in the CCV. These 
data are difficult to compare with other studies be-
cause in our study the majority of patients with CDI 
were treated at the Infectious Diseases Clinic and not 
in the healthcare facilities where the infection had oc-
curred. This policy at the Clinical Center of Vojvodina 
is the result of insufficient means to provide suitable 
patient isolation and implementation of appropriate 
measures  for  infection  control  and  prevention.  In 
most countries, patients are treated in the healthcare 
facilities where the infection was acquired (Centers 
for Disease Control and Prevention (CDC), 2012).
CDAD are diseases with significant financial im-
pact (Stefan-Mikić et al., 2011). In the last five years, 
the  occurrence  of  CDI  is  raising  concerns  in  the 
CCV and requires the reevaluation of patient treat-
ment costs and the economic consequences of this 
occurrence. In our study, we showed the material 
costs of treatment in the initial episode of CDI and in 
recurrent infections. Total material costs include the 
cost of laboratory tests and diagnostic procedures, 
costs of antimicrobial therapy, drug therapy for co-
morbidities and the cost of sanitary and medical staff 
expenditure. 
Total hospital costs related to the presence of CDI 
in the period from 2008 to2012 at the Infectious Dis-
eases Clinic, CCV, were $ 636,679.92. The total hospi-
tal costs of treatment for CDI patients in 2008, 2009, 
2010, 2011 and 2012 were $132,592.65, $108,887.78, 
$156,232.99,  $133,445.15  and  $105,521.35  respec-
tively. The highest cost for the treatment of a single 
patient reached $7,534. In this five-year period, the 
greatest costs for CDI therapy were registered at the 
Clinic of Urology and they amounted to $58,090.61 
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The average cost of treatment per case of initial 
CDI was about $1,149.03 and $1,081.74 for recurrent 
CDI (p=0.14, p>0.05). The average cost of treatment 
per day of CDI was about $1,131.90. There was no 
statistically significant difference between the aver-
age cost of treatment per day of initial and recurrent 
CDI ($97.19 vs. $103.47, p=0.67, p> 0.05).
The  coverage  and  structure  of  the  CDI  treat-
ment costs vary from country to country. Different 
study designs, different numbers of patients and size 
of medical facilities as well as varieties in medical 
health systems worldwide make these data hard to 
compare. All studies in the last decade emphasize the 
significantly higher average cost of treating patients 
with CDI compared to other non-CDI patients and 
confirm that nosocomial CDAD is associated with 
85% higher average costs (Pakyz et al., 2011). 
Cumulative annual hospital healthcare costs due 
to C. difficile disease are estimated to be $1.1 billion 
in the US and in Europe the annual cost is estimated 
to $3 billion (Schneider et al., 2007). According to 
our knowledge, we do not have official data on the 
total material cost of CDI treatment in Serbia. 
A treatment protocol with oral vancomycin in a 
dose of 250 mg four times a day compared to other 
treatment protocols (p = 0.000, p <0.05) was signifi-
cantly more often used, because the majority of pa-
tients had already terminated one course of metro-
nidazole therapy before admission to the Infectious 
Diseases Clinic. Results from clinical studies in the 
nineties  of  the  last  century,  established  metronida-
zole as a first line therapy in the treatment of initial 
episodes of CDAD due to its significantly lower price 
and similar clinical efficacy compared to vancomycin. 
However, recent clinical studies advocate vancomycin 
as the drug of choice in the treatment of severe CDAD 
(Vaishnavi, 2010). According to the latest IDSA guide-
lines (Infectious Disease Society of America) (Cohen 
et al., 2010) as well as European Society of Clinical 
Microbiology and Infectious Diseases guidelines (ES-
CMID) (Bauer et al., 2009), the treatment choice for 
the initial episode of CDI depends on the severity of 
the disease.
There  was  no  significant  difference  between 
mean length of stay for initial episode of CDI and 
length of stay in recurrent CDI in our study (12.13 vs. 
12.32, p=0.96, p>0.05). Cheng et al. (2011) presented 
data on the average length of hospital stay for the ini-
tial CDI of 8.7 days, and length of hospitalization for 
recurrent CDI of 13.6 days, which corresponds to the 
results of our study.
Recurrent CDI occurred in 26.27% of our pa-
tients,  which  correlates  with  literature  data  where 
15-55% of patients with a good therapeutic response 
after the initial episode of CDI develop a recurrent 
form. The mortality rate during the study period was 
6.51%, which corresponds to the data from US litera-
ture where the mortality rate was about 9.4% (Stew-
art et al., 2011).
In order to decrease the incidence and cost of 
treating patients with CDI, the Society for Health-
care Epidemiology of America (SHEA) and Infec-
tious  Disease  Society  of  America  (IDSA)  issued 
clinical guidelines recommending a reduction in fre-
quency and duration of antibiotic therapy as well as 
implementation of infection control measures such 
as isolation of infected persons, proper handling of 
the patient and disinfection of contaminated surfac-
es with 10% chlorinated disinfectants (Cohen et al., 
2010 and Bauer et al., 2009).
CONCLUSION
Total hospital costs related to presence of CDI in 
period  from  2008  to  2012  at  the  Infectious  Dis-
eases Clinic, Clinical Center of Vojvodina, were $ 
636,679.92. The highest material costs for treatment 
of CDI patients in the period from 2008-2012, and 
were registered at the Clinic of Urology. The thera-
peutic protocol commonly used for the treatment of 
initial CDI is a ten-day treatment with oral vancomy-
cin at a dose of 250 mg four times a day, and its cost 
is $4,276.80. The average mortality rate during the 
study period was 6.51%. Infection control measures 
and the control of antibiotic use would significantly 
reduce material costs for the treatment of this disease 
and allow for the redirection of material resources 64 SANDRA STEFAN-MIKIĆ ET AL.
within the healthcare system.
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